Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline to use 4,000 patients for diabetes drug trial

GlaxoSmithKline to use 4,000 patients for diabetes drug trial

18th February 2009

GlaxoSmithKline (GSK) has announced more than 4,000 patients will take part in its phase III clinical trial of a new drug aimed to treat those with type 2 diabetes.

The study is expected to take two to three years and will assess the efficacy, safety and tolerability of the investigational Glucagon-like peptide 1 (GLP-1) against albiglutide (Syncria) in both men and women – starting with five studies at the beginning of 2009.

Senior vice-president at Biopharm Development for the company Dr Carlo Russo explained the purpose of the trial is to try and improve the lives of those with this form of diabetes by finding improved ways of manage it.

He stated: “Albiglutide is a novel biological currently being investigated to determine its potential to help people control their blood sugar, particularly when oral treatments alone may not provide an adequate response.”

The medication is designed to work for longer in the body and should allow for weekly or less-frequent injections. Patients taking part in the trial will receive 30 milligrams every seven days.

GSK is a research-based pharmaceutical and healthcare company.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.